



## Announcement Summary

---

**Entity name**

IMAGION BIOSYSTEMS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

7/3/2023

**The Proposed issue is:**

A standard pro rata issue (including non-renounceable or renounceable)

**Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)**

ASX +security code	+Security description	Maximum Number of +securities to be issued
IBX	ORDINARY FULLY PAID	140,164,817

**Ex date**

9/3/2023

**+Record date**

10/3/2023

**Offer closing date**

30/3/2023

**Issue date**

6/4/2023

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of +Entity

IMAGION BIOSYSTEMS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

### 1.2 Registered Number Type

ACN

### Registration Number

616305027

### 1.3 ASX issuer code

IBX

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

7/3/2023

### 1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

### 1.6a The proposed standard +pro rata issue is:

+ Non-renounceable



Part 3 - Details of proposed entitlement offer issue

---

Part 3A - Conditions

---

**3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?**

No

Part 3B - Offer details

---

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +security code and description**

IBX : ORDINARY FULLY PAID

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

**If the entity has quoted company options, do the terms entitle option holders to participate on exercise?**

No

Details of +securities proposed to be issued

---

**ASX +security code and description**

IBX : ORDINARY FULLY PAID

**ISIN Code (if Issuer is a foreign company and +securities are non CDIs)**

**ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities are non CDIs)**

**Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)**

**The quantity of additional +securities to be issued**

1

**For a given quantity of +securities held**

8



**What will be done with fractional entitlements?**

Fractions rounded up to the next whole number

**Maximum number of +securities proposed to be issued (subject to rounding)**

140,164,817

**Offer price details for retail security holders**

**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security for the retail offer?**

AUD 0.01700

**Oversubscription & Scale back details**

**Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?**

Yes

**Describe the limits on over-subscription**

Eligible Shareholders who take up their full Entitlement will be able to apply for additional Shares over and above their Entitlement under the Top-Up Facility. The Directors do not intend to refuse an application for additional Securities under the Top-Up Facility from Eligible Shareholders other than in the circumstances of oversubscription or where acceptance may result in that Eligible Shareholder taking their voting power to over 19.9% or breaching the Corporations Act.

**Will a scale back be applied if the offer is over-subscribed?**

Yes

**Describe the scale back arrangements**

The Company reserves the right to scale back any applications for Additional Securities in its absolute discretion. When determining the amount (if any) by which to scale back an application, the Company may take into account a number of factors, including but not limited to the size of an Applicant's shareholding in the Company.

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

---

Part 3C - Timetable

**3C.1 +Record date**

10/3/2023



**3C.2 Ex date**

9/3/2023

**3C.4 Record date**

10/3/2023

**3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue**

15/3/2023

**3C.6 Offer closing date**

30/3/2023

**3C.7 Last day to extend the offer closing date**

27/3/2023

**3C.9 Trading in new +securities commences on a deferred settlement basis**

31/3/2023

**3C.11 +Issue date and last day for entity to announce results of +pro rata issue**

6/4/2023

**3C.12 Date trading starts on a normal T+2 basis**

11/4/2023

**3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis**

13/4/2023

Part 3E - Fees and expenses

---

**3E.1 Will there be a lead manager or broker to the proposed offer?**

Yes

**3E.1a Who is the lead manager/broker?**

Shaw and Partners Limited

**3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

For proceeds of less than \$2 million a management fee of 5.0% and a selling fee of 5.0% of proceeds from the offer. For proceeds of \$2 million or more a minimum fee of \$200,000 or a management fee of 3.0% and a selling fee of 3.0% of the proceeds from the offer (whichever is greater).

**3E.2 Is the proposed offer to be underwritten?**

No



**3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No

**3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Part 3F - Further Information

---

**3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

Funds raised under the Offer will be used to prepare the Company's lead imaging agent for the next phase of clinical development, pipeline growth such as prostate and ovarian cancer and additional working capital.

**3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?**

No

**3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?**

No

**3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue**

This Offer will only be extended to security holders with a registered address in Australia or New Zealand.

**3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities**

Yes

**3F.5a Please provide further details of the offer to eligible beneficiaries**

This Offer will only be made available eligible nominees or custodians with a registered address in Australia or New Zealand who are registered security holders on the Record Date.

**3F.6 URL on the entity's website where investors can download information about the proposed issue**

<https://imaginationbiosystems.com/investor-hub/>

**3F.7 Any other information the entity wishes to provide about the proposed issue**

**3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?**

No

**3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)